|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Efficacy and Safety of ME3183 Administered Orally in Subjects With Moderate to Severe Plaque Psoriasis
The purpose of this study is to assess the efficacy and safety of ME3183 administered orally for moderate to severe plaque psoriasis in adults.
100 Clinical Results associated with Meiji Seika Pharma Co. Ltd. (United States)
0 Patents (Medical) associated with Meiji Seika Pharma Co. Ltd. (United States)
100 Deals associated with Meiji Seika Pharma Co. Ltd. (United States)
100 Translational Medicine associated with Meiji Seika Pharma Co. Ltd. (United States)